Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-04-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.42 |
| _version_ | 1797200040892039168 |
|---|---|
| author | Ricardo Lopez Santi Felipe Martinez Adrian Baranchuk Alvaro Sosa Liprandi Daniel Piskorz Alberto Lorenzatti Juan Carlos Kaski |
| author_facet | Ricardo Lopez Santi Felipe Martinez Adrian Baranchuk Alvaro Sosa Liprandi Daniel Piskorz Alberto Lorenzatti Juan Carlos Kaski |
| author_sort | Ricardo Lopez Santi |
| collection | DOAJ |
| description | Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps between guidelines and best daily clinical practice still persist. The International Society of Cardiovascular Pharmacotherapy designed the Surveillance of Prescription Drugs in the Real World Project (VIPFARMA ISCP), a survey for physicians who manage lipid disorders in high-risk patients. Seven clusters of questions will be analysed comprising demographics, institution profile, access to continuing medical education, clinical practice profile, attitude regarding use of statins, knowledge regarding proprotein convertase subtilisin/kexin type 9 inhibitors and attitudes regarding medical decisions about triglycerides. The present study will be the first part of a larger programme and aims to shed light on barriers between lipid-lowering drug therapy recommendations in the 2019 European Society of Cardiology guidelines and clinical practice in different countries. |
| first_indexed | 2024-03-07T17:40:48Z |
| format | Article |
| id | doaj.art-4cc6b34f5eb04d13b4ba90713e405361 |
| institution | Directory Open Access Journal |
| issn | 1758-3756 1758-3764 |
| language | English |
| last_indexed | 2024-04-24T07:25:20Z |
| publishDate | 2021-04-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj.art-4cc6b34f5eb04d13b4ba90713e4053612024-04-20T16:02:12ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-04-011610.15420/ecr.2020.42Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP ProjectRicardo Lopez Santi0Felipe Martinez1Adrian Baranchuk2Alvaro Sosa Liprandi3Daniel Piskorz4Alberto Lorenzatti5Juan Carlos Kaski6Division of Cardiology, Hospital Italiano de La Argentina, La Plata, Buenos Aires, ArgentinaInstituto Médico DAMIC-Fundacion Rusculleda, Cordoba, ArgentinaDepartment of Medicine, Queen’s University, Kingston, Ontario, CanadaDivision of Cardiology, Sanatorio Guemes, Buenos Aires, ArgentinaCardiovascular Institute of the Rosario British Sanatorium, Santa Fe, ArgentinaDAMIC-Rusculleda Foundation, National University of Córdoba, Cordoba, ArgentinaMolecular and Clinical Sciences Research Institute, St George’s, University of London, London, UKDyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps between guidelines and best daily clinical practice still persist. The International Society of Cardiovascular Pharmacotherapy designed the Surveillance of Prescription Drugs in the Real World Project (VIPFARMA ISCP), a survey for physicians who manage lipid disorders in high-risk patients. Seven clusters of questions will be analysed comprising demographics, institution profile, access to continuing medical education, clinical practice profile, attitude regarding use of statins, knowledge regarding proprotein convertase subtilisin/kexin type 9 inhibitors and attitudes regarding medical decisions about triglycerides. The present study will be the first part of a larger programme and aims to shed light on barriers between lipid-lowering drug therapy recommendations in the 2019 European Society of Cardiology guidelines and clinical practice in different countries.https://www.ecrjournal.com/articleindex/ecr.2020.42 |
| spellingShingle | Ricardo Lopez Santi Felipe Martinez Adrian Baranchuk Alvaro Sosa Liprandi Daniel Piskorz Alberto Lorenzatti Juan Carlos Kaski Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project European Cardiology Review |
| title | Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project |
| title_full | Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project |
| title_fullStr | Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project |
| title_full_unstemmed | Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project |
| title_short | Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project |
| title_sort | management of dyslipidaemia in real world clinical practice rationale and design of the vipfarma iscp project |
| url | https://www.ecrjournal.com/articleindex/ecr.2020.42 |
| work_keys_str_mv | AT ricardolopezsanti managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT felipemartinez managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT adrianbaranchuk managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT alvarososaliprandi managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT danielpiskorz managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT albertolorenzatti managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT juancarloskaski managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject |